SC-type Remsima starts to aim for TNF-α inhibitor market
Celltrion started to conduct a clinical trial of the SC-type of Remsima, an autoimmune treatment, expanding its product competitiveness in the TNF-α inhibitor market. The company announced acquisition of the Phase 1 clinical trial approval of the autoimmune treatment ‘CT-P13 SC(hereinafter referr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
